However, inherited BRCA1/2 mutations are present in 13-15% of OC (17), most frequently (18% in high-grade serous carcinomas) and less commonly for other histologic subtypes (18) and many cancer patients with BRCA1/2-wt tumors, sensitization to the different DNA-damaging agents with PARPi is less effective. This evidence concerns the gene BRCA1 and serous adenocarcinoma.